VJHemOnc Podcast
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
Nov 24, 2023
Guests Angela Dispenzieri, MD, Paolo Lopedote, MD, and Vaishali Sanchorawala, MD discuss unmet needs in AL amyloidosis, including early diagnosis and optimal treatment strategies. They explore the prevalence and impact of CHIP in amyloidosis patients, as well as alternative treatment options for those who cannot undergo stem cell transplantation. The speakers also discuss refining hematologic response criteria and assessing residual disease in AL amyloidosis treatment.
12:23
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Early diagnosis and treatment are crucial in AL amyloidosis to prevent irreversible organ damage and improve overall survival.
- Clonal hematopoiesis of indeterminate potential (CHIP) may have an impact on prognosis and renal stage in AL amyloidosis, further research is needed to understand its significance.
Deep dives
Unmet Needs in the Diagnosis and Treatment of Light Chain Amyloidosis
Early diagnosis and treatment of light chain amyloidosis is crucial to prevent irreversible organ damage and increase overall survival. There is a lack of consensus regarding the best therapies and combinations for relapsed cases. Immunotherapy strategies used in multiple myeloma have not been thoroughly explored in the amyloidosis space. Optimizing progression criteria is necessary for drug approval by regulatory agencies. The use of different immunotherapy strategies and novel therapies like neetoclax shows promise in achieving better outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
